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Abstract: This paper proposes a novel criterion for the allocation of
patients in Phase I dose-escalation clinical trials aiming to find the max-
imum tolerated dose (MTD). Conventionally, using a model-based ap-
proach the next patient is allocated to the dose with the toxicity estimate
closest (in terms of the absolute or squared distance) to the maximum
acceptable toxicity. This approach, however, ignores the uncertainty in
point estimates and ethical concerns of assigning a lot of patients to
overly toxic doses. Motivated by recent discussions in the theory of es-
timation in restricted parameter spaces, we propose a criterion which
accounts for both of these issues. The criterion requires a specification
of one additional parameter only which has a simple and intuitive inter-
pretation. We incorporate the proposed criterion into the one-parameter
Bayesian continual reassessment method (CRM) and show, using sim-
ulations, that it results in the same proportion of correct selections
on average as the original design, but in fewer mean number of toxic
responses. A comparison to other model-based dose-escalation designs
demonstrates that the proposed design can result in either the same
mean accuracy as alternatives but fewer number of toxic responses, or
in a higher mean accuracy but the same number of toxic responses. We
conclude that the new criterion makes the existing model-based designs
more ethical without losing efficiency in the context of Phase I clinical
trials.
Keywords and phrases: Allocation Rule, Continual Reassessment
Method, Loss Function, Phase I Clinical Trial, Restricted Parameter
Space.
1. Introduction
Consider a Phase I clinical trial with two doses (d1, d2) and a binary end-
point, dose-limiting toxicity (DLT) or no DLT, to stress the importance of
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an allocation criterion. The goal of the trial is to find the maximum tolerated
dose (MTD) which has a probability of a DLT closest to the pre-specified
target, say γ = 0.30. Assume that 10 patients were assigned to each dose and
2 and 4 toxicities are observed, respectively. Then, a typical question in a
sequential trial is: “which dose should be administered to the next patient”.
A conventional criterion for many dose-escalation model-based designs (see
e.g. O’Quigley et al., 1990; Wages et al., 2011) is to assign the next patient
to dose di corresponding to the point estimate pˆi closest to γ in terms of the
absolute or, equivalently, the squared distance
(pˆi − γ)2 . (1)
Assume that in the example above, the probabilities p1 and p2 are considered
as random variables with Beta distributions B(2, 8) and B(4, 6) and one uses
the mean as the point estimate: pˆ1 = 0.2 and pˆ2 = 0.4. Following criterion (1),
the next patient can be allocated to either of doses as both estimates are
equally close to the target. At the same time, one can argue that these doses
are not “equal” for at least two reasons. On the one hand, the criterion (1)
ignores the randomness of the estimates. Indeed, the probability of being
within 5% of γ is larger for p2
P (p2 ∈ (0.25, 0.35)) > P (p1 ∈ (0.25, 0.35)) . (2)
The larger variance of p2 favours the decision to allocate the next patient to
d2. On the other hand, the allocation of a patient to the dose with estimated
toxicity probability of 0.4 can be considered to be unethical as it exposes a
patient to an unacceptably high toxicity. Moreover, it is usually of interest
to balance these two aims in a Phase I clinical trial - an investigator would
like to study more doses but would like to avoid exposing patients to doses
far from the MTD. In the illustration above, the criterion (1) fails to address
both of these concerns.
The question of safety was firstly addressed by Babb et al. (1998) using
the Escalation with Overdose Control (EWOC) design. The EWOC uses the
criterion
E
(
α(γ − pi)+ + (1− α)(pi − γ)+
)
(3)
for patients allocations (Cheung, 2011), where (x)+ = max(0, x) and α is a
parameter of asymmetry. The criterion (3) imposes that the allocation to a
more toxic dose should have a more severe penalty than to a less toxic one.
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The EWOC design has been shown to result in a low average number of
DLTs. However, it also leads to underestimation of the MTD in many real-
istic scenarios and some modifications were recently proposed by Tighiouart
et al. (2010); Wheeler et al. (2017). Another design aimed to resolve both the
uncertainty and safety concerns is the Bayesian Logistic Regression Model
(BLRM) by Neuenschwander et al. (2008). To address the first concern, it
is proposed to use the whole distribution of the DLT probability, while the
ethical one is addressed via a penalty to overly toxic intervals. The allocation
is determined by a loss function computed for each dose. While this approach
has been proven to be useful in practice, it requires specifying several param-
eters (values of the loss function and corresponding intervals) on which the
operating characteristics of the design can depend on significantly.
In this work, we propose a new criterion for the allocation of patients in
dose-escalation trials. A point estimate of the criterion takes both the vari-
ance of the distribution of probability toxicity and the ethical concerns of
an investigator into account. The novel criterion requires only one additional
parameter, which has a simple and intuitive interpretation, to be specified.
This parameter controls the trade-off between the uncertainty in estimates
and the conservative of an investigator (in terms of the mean number of toxic
responses). The novel criterion is defined as the squared distance generalised
to a parameter defined on the restricted parameter space (the unit interval)
as proposed by Mozgunov and Jaki (2018b); Mozgunov et al. (2018). As it is
generally agreed that model-based Phase I designs lead to better operating
characteristics than rule-based alternatives (Reiner et al., 1999), we incorpo-
rate the proposed criterion into the Bayesian continual reassessment method
(O’Quigley et al., 1990, CRM) and compare its operating characteristics to
the traditional one-parameter power model CRM design, the EWOC design
and its recent modifications, and the BLRM design.
Importantly, we will focus on the application of the novel criterion to the
one-parameter power model as it has been shown (O’Quigley and Shen, 1996;
Zohar and Chevret, 2001; Cheung, 2011; Iasonos et al., 2016) to be able to
identify the MTD with a high probability. Note, however, that the proposed
criterion is generic and can be applied to any parametric model (for instance,
the two-parameter logistic model) if it is preferred by an investigator.
The rest of the paper proceeds as follows. The new criterion and its prop-
erties are studied in Section 2. The application of the novel criterion in the
context of an actual clinical trial is considered in Section 3. A simulation
comparison to the traditional continual reassessment method is given in Sec-
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tion 4. A comparison to the EWOC-type and BLRM designs are given in
Section 5. Section 6 concludes with a discussion.
2. Methods
2.1. Criterion
Consider a Phase I clinical trial with binary DLT outcomes and m doses
d1, . . . , dm. The main estimation objective in a such Phase I trial is the prob-
ability of DLT pi ∈ (0, 1) if dose di was given to a patient. Once estimates of
pi are obtained, an investigator selects the MTD as the dose associated with
the toxicity probability closest to γ ∈ (0, 1). Let us consider the criterion (1)
for some fixed dose d and the associated probability p. It is argued by Aitchi-
son (1992), that the criterion (1) might not be a reliable measure of distance
between objects defined on restricted parameter spaces. This argument is
valid in the considered setting as both p and γ are defined on the restricted
space - the unit interval. As an alternative, Aitchison (1992) proposed a new
distance between p and γ
AD(p, γ) =
√(
log
p
1− p − log
γ
1− γ
)2
, p, γ ∈ (0, 1) (4)
known as the Aitchison distance. However, the Aitchison distance lacks some
important properties such as convexity and a closed form solution for the
corresponding minimizer (Mozgunov et al., 2018). Instead, the convex unit
interval symmetric distance
δ(p, γ) =
(p− γ)2
p(1− p) . (5)
was proposed by Mozgunov et al. (2018) which we use to construct the crite-
rion for the allocation of patients. Criterion (5) still has the squared distance
term in the nominator which ensures that it takes its minimum value δ(·) = 0
at p = γ. At the same time, the denominator represents the variance of the
probability of a binary event. Then, criterion (5) can be considered a score
statistic which takes into account the uncertainty of the estimation object.
In the context of the Phase I trial, the denominator can have one more inter-
pretation. If p = 0 or p = 1 then δ(·) = ∞ meaning that patients would be
never allocated to doses corresponding to 0 or 1 DLT probabilities. Indeed,
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the property of assigning of infinite values to the extreme values “drives
away” the selection from the bounds to the neighbourhood of the interval
of interest γ (Mozgunov and Jaki, 2018b; Saint-Hilary et al., 2018). Impor-
tantly, the criterion (5) also has an information-theoretic justification as it
maximises the information gain in the trial with the area of the special inter-
est, the neighbourhood of the maximum acceptable toxicity (Mozgunov and
Jaki, 2018a).
Applying the criterion to the illustration example above helps to address
the uncertainty issue as
δ(pˆ1 = 0.2, γ = 0.3) = 1/16 and δ(pˆ2 = 0.4, γ = 0.3) = 1/24.
This means that d2 should be selected for a next patient as follows from
Inequality (2). Note that a single point estimate of the criterion (5) already
summarises the information about uncertainty in itself which can provide a
potential computational benefits.
The target toxicity γ is always less than 0.5 in Phase I clinical trials.
Consequently, if one would consider two point estimates which stand on the
same squared distance (γ−θ)2 from the γ (for θ < γ), the criterion (5) favours
a higher probability estimate due to the variance term in the denominator
which is maximised at the point p = 0.5. Indeed, the same rate of terms p
and (1−p) in the denominator implies that overly toxic and overly safe doses
are equally penalised. This, however, might contradict with the ethical issues
of a trial.
To address this issue we generalise the criterion (5) to the case of asym-
metric penalisation by including the asymmetry parameter a:
δ(p, γ) =
(p− γ)2
pa(1− p)2−a . (6)
The parameter 0 < a < 2 corresponds to the penalisation of overly toxic
doses and 2−a to overly safe doses. The constant 2 is chosen to preserve the
same rate of p in both nominator and denominator to guarantee that δ → 0
when p→ γ for all values of γ. Clearly, values 0 < a < 1 imply a more severe
penalty for the allocation of patients to more toxic doses than to less toxic
ones. Applying the proposed criterion with asymmetry parameter a = 0.5
one can obtain that
δ(pˆ1 = 0.2, γ = 0.3, a = 0.5) < δ(pˆ2 = 0.4, γ = 0.3, a = 0.5)
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which means that dose d1 would be selected due to the penalty on overly
toxic doses. We would refer to the proposed criterion (6) as to the Convex
Infinite Bounds Penalization (CIBP). An illustration of the squared distance
criterion (1) and of the CIBP criterion (5) using a = 1 and a = 0.5 is given
in Figure 1.
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Fig 1. Squared distance criterion (dotted line) and CIBP criterion using the asymmetry
parameter a = 1 (dashed line), a = 0.5 (solid line) for the target toxicity γ = 0.3 and for
different values p ∈ (0.05, 0.6).
The CIBP criterion (for both a = 1 and a = 0.5) goes to infinity faster than
the squared distance as the probability p approaches the lower bound. At the
same time, for a = 1 overly toxic doses are penalised less than by alternatives
because corresponding values of the toxicity probability are located far from
another boundary value 1. The asymmetric CIBP criterion with a = 0.5
solves this issue and penalises overly toxic doses more severely than both
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the squared distance and the symmetric CIBP. Note that all criteria behave
similarly in the neighbourhood of the target γ. Overall, one can see that the
properties of the proposed criterion allow resolving the ethical concern by
setting an appropriate value of the parameter a. Further guideline on the
choice of a is given in the following section.
2.2. Choice of the asymmetry parameter
Firstly, note that the denominator alone is maximised at the point p = a/2.
Then, if pˆ is an estimator of p (depending on the approach, for instance,
MLE or the Bayesian optimal estimator) the “plug-in” estimator of the CIBP
criterion
δ(pˆ, γ) =
(pˆ− γ)2
pˆa(1− pˆ)2−a (7)
using a = 2γ leads to the same allocation as a plug-in estimator of the squared
distance (1). Then, values a < 2γ imply a more conservative allocation of
patients than an original design which uses the squared distance criterion.
Secondly, the asymmetry parameter a represents the trade-off between the
ethical and uncertainty concerns. Then, for a sensible choice of a we use the
following condition. Consider an interval (γ−θ, γ+θ). Assume that given two
point toxicity probability estimates belonging to this interval and standing
on the same squared distance from γ, one would like to select the lower
toxicity estimate due to the safety concern. In other words, (γ − θ, γ + θ)
is the interval in which the safety issue is prioritised. Similarly, given two
estimates lying outside of the interval (γ − θ, γ + θ), but standing on the
same squared distance, one would select that one which corresponds to a
higher level of the uncertainty. Evidently, the estimates lying on the bounds
of this interval should correspond to the same value of the CIBP criterion.
Formally, solving
((γ − θ)− γ)2
(γ − θ)a (1− (γ − θ))2−a =
((γ + θ)− γ)2
(γ + θ)a (1− (γ + θ))2−a
one can obtain that
a =
2
1 + A
where
A =
(
log
γ − θ
γ + θ
)
/
(
log
1− γ − θ
1− γ + θ
)
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Then, for the fixed target value of γ and the half-width of the interval θ, one
can compute the corresponding value of a. Figure 2 shows the dependence
of the asymmetry parameter on the half-width θ and the target probabilities
γ = {0.20, 0.25, 0.30}.
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Fig 2. The values of parameter of asymmetry for γ = 0.20 (dashed-dotted line) , γ = 0.25
(solid line), γ = 0.30 (dashed line) and different values of θ ∈ (0, 0.35). The horizontal
line corresponds to the choice of a = 0.30 and corresponding half-width of intervals.
As θ → 0 (the uncertainty issue is prioritised), a tends to 2γ which choice
corresponds to the squared distance allocation rule as shown above. Increas-
ing values of θ correspond to a wider interval in which an investigator prefers
a lower toxicity estimate. Consequently, this corresponds to a more conser-
vative allocation and to smaller values of a. Note that a corresponding to
θ ≈ γ guarantees that for two estimates standing on the same squared dis-
tance from the target γ, the dose corresponding to the lower toxicity estimate
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would be always selected. For example, for the target value γ = 0.25 and the
half-width θ = 0.245, the corresponding value of a is close to 0.3 (marked by
the dotted horizontal line in Figure 2).
In the next section, we recall the Bayesian continual reassessment method
by O’Quigley et al. (1990) and incorporate the proposed allocation criterion
in the design.
2.3. Bayesian continual reassessment method
Consider a Phase I clinical trial with m doses and n patients. Assume that
the DLT probability has the functional form
pi = ψ(di, β)
where β ∈ Rh is a h-dimensional vector of parameters and di, i = 1, . . . ,m are
standardised dose levels. Denote the prior distribution of β by f0(.). Assume
that j patients have already been assigned to doses d(1), . . . , d(j) and binary
responses Yj = [y1, . . . , yj]T were observed. The CRM updates the posterior
distribution of β using Bayes’s Theorem
fj(β) =
fj−1(β)φ(d(j), yj, β)∫
Rh fj−1(u)φ(d(j), yj, u)du
=
f0(β)
∏j
i=1 φ(d(i), yi, β)∫
Rh f0(u)
∏j
i=1 φ(d(i), yi, u)du
(8)
where
φ(d(j), yj, β) = ψ(d(j), β)
yj(1− ψ(d(j), β))1−yj .
Then, the posterior mean of the DLT probability for dose di after j patients
is equal to
pˆ
(j)
i = E(ψ(di, β)|Yj) =
∫
Rh
ψ(di, u)fj(u)du. (9)
As it was outlined above, the original design uses the following criterion. The
dose dk minimising
(pˆ
(j)
i − γ)2 (10)
among all d1, . . . , dm is selected for the next group of patients. We propose
to replace this step by the following allocation rule. The dose dk minimising
E
(
(ψ(di, β)− γ)2
ψ(di, β)a(1− ψ(di, β))2−a
)
(11)
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among all d1, . . . , dm is selected for the next group of patients where the
expectation is found w.r.t. to the posterior probability fj(β). The procedure
is repeated until the maximum number of patients, n, has been treated. As
the uncertainty and the conservatism is important in the allocation only, we
propose to use the squared distance (10) for the final MTD selection.
Many implementations of the CRM plug the mean value of β in the model
ψ(di, βˆ) instead of using the mean value, E(ψ(di, β)|Yj). While no noticeable
difference is found in these approaches if a one-parameter model is used (Ia-
sonos et al., 2016), it might affect the results significantly if more complex
functions are considered. Therefore, the posterior mean of the new criterion
is used. For consistency across all designs, we would also use the mean prob-
ability estimate while performing the original CRM design.
We concentrate on the one-parameter power model
ψ(di, β) = d
exp(β)
i (12)
which was shown to be a powerful tool to identify the MTD. As the final
remark, there are no concerns about the CRM design to be not aggressive
enough. Therefore, we would concentrate on values a ≤ 2γ in the rest of the
work.
3. Application to an actual clinical trial
3.1. Setting
To illustrate the impact of the proposed allocation criterion, we revisit the
results of the actual clinical trial of Everolimus in Patients With HER2-
overexpressing Metastatic Breast Cancer (NCT00426556). The study consid-
ers 3 regimens of Everolimus given together with Paclitaxel and Trastuzumab (PT):
1. Daily dosing of Everolimus 5mg plus PT (d1)
2. Daily dosing of Everolimus 10mg plus PT (d2)
3. Weekly dosing of Everolimus 30mg plus PT (d3)
The goal is to find the regimen corresponding to the target toxicity γ = 0.3.
Note that the amount of the complimentary drugs is fixed during the trial and
a clinician is confident in the monotonic relationship of toxicity probabilities
for d1, . . . , d3. Thus, the trial can be analysed using the tools for the single-
agent trials. The aggregated data available by the end of the trial is given in
Table 1. We revisit the results of this trial using the novel allocation criterion.
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Table 1
Aggregated data of the Everolimus trial
Dose d1 d2 d3
Number of Patients assigned 6 17 10
Number of DLTs 3 6 7
We apply the CRM design using the one-parameter power model 12 us-
ing the robust operational prior distribution β ∼ N (0, 1.34) (O’Quigley and
Shen, 1996; Cheung, 2011) and the skeleton (0.20, 0.30, 0.40) with an ad-
equate spacing (O’Quigley and Zohar, 2010) and implying that the prior
MTD is d2. We restrict the design so that the dose skipping is not allowed
and enforce starting from the lowest dose. Patients are enrolled in cohorts of
3. Note that the parameters of the design are the same for both the original
CRM and the CRM using the novel allocation rule. The only difference is
the criterion for the selection of doses. The original CRM uses the squared
distance (10) while the CIBP design uses the criterion (11). Following the
interpretation of the asymmetry parameter, we fix a = 0.3 to favour less
toxic selections in a wide interval of toxicity probabilities. The designs are
implemented using the interactive functions of the bcrm-package by Sweeting
et al. (2013). We use the aggregated data from Table 1 to generate the re-
sponses in one realisation of the trial. Clearly, DLTs indicated in Table 1 can
appear in any sequence. Therefore, we generate a random sample (without
replacement) for each dose to have a specific order of DLTs. We fix this order
for both trials. The only exception is that the realisation for the first cohort
is chosen by us. We consider the influence of this choice later.
3.2. Illustration
The first 3 patients are assigned to d1 by construction. We begin by assuming
that all 3 patients have not experienced DLTs. The sequential dose selections
for the CRM and CIBP designs, in this case, are given in Figure 3. The values
of the criteria after each cohort are given in Table 2.
After no DLTs were observed for the first cohort, CRM and CIBP allocate
the second cohort of patients to d2 for which one patient experiences a DLT.
Given this toxic outcome, CRM recommends to stay at d2 for the third cohort.
In contrast, CIBP recommends returning to the previous dose level due to
the conservatism of the criterion. Then, after all patients in cohort 3 (using
CIBP) experienced the DLT, the trial would be terminated by a clinician due
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Fig 3. Allocation of 7 cohorts in the individual Everolimus trial.
to safety. At the same time, the trial using the original CRM design proceeds.
After no DLTs were observed for cohort 3, d3 is recommended for cohort 4
in which all patients have DLT. This leads to de-escalation to d2 and after
2 cohorts for which 3 patients (out of 6) had DLT and further de-escalation
to d1. All 3 patients in cohort 7 experienced DLTs and a clinician terminates
a trial due to toxicity. Overall, while the CRM assigned 21 patients and 10
of them experienced DLTs to come to the same conclusion as CIBP, the
novel criterion allows to reduce the sample size to 9 patients with 4 toxicity
outcomes only.
The illustration above demonstrates the allocation if no toxicity outcomes
are observed in cohort 1, but other possibilities should be considered as well
based on aggregated data. Clearly, the other possibilities are 1, 2 and 3 DLTs
in the first cohort. Considering these scenarios, it was found that both designs
lead to the same allocation of patients and never escalate from dose d1. It
follows that the novel allocation rule leads to the same MTD selection in all
possible sequence of outcomes, but results in fewer or similar number of toxic
responses. This motivates a further investigation of the novel criterion in a
comprehensive simulation study.
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Table 2
The values of criterion (10) used by the CRM and criterion (11) used by CIBP
in the individual trial after each cohort. The value of criterion corresponding to
the dose selected for next cohort by each design is in bold
CRM CIBP
Cohort 1 0.031 0.012 0.002 0.62 0.47 0.45
Cohort 2 0.01 0.001 0.005 0.10 0.12 0.21
Cohort 3 0.03 0.013 0.001 0.30 0.67 1.41
Cohort 4 0.003 0.002 0.003
Cohort 5 0.003 0.002 0.024
Cohort 6 0.000 0.009 0.039
Cohort 7 0.014 0.048 0.096
4. Comparison to the original CRM
4.1. Setting
In this section, we compare the performance of the proposed criterion against
the squared distance criterion both applied to the one-parameter power
model. The single-agent Phase I trial with m = 6 doses and n = 30 pa-
tients is considered. The goal is to find the MTD corresponding to γ = 0.25.
We consider 6 dose-toxicity scenarios with the target doses located at the
dose corresponding to scenario’s number. The shapes of the dose-toxicity are
given in Figure 4. Toxicity scenarios were chosen “equally difficult” in terms
of the optimal non-parametric benchmark (O’Quigley et al., 2002). It allows
comparing the proportion of correct selections (PCS) between different sce-
narios. We specify the skeleton for the one-parameter power model using the
package dfcrm and the function getprior using that the prior MTD is d2
and the half-width of the equivalent interval is 0.05. The prior distribution
of the parameter is chosen to be β ∼ N (0, 1.34) (O’Quigley and Shen, 1996;
Cheung, 2011, 2013). Different skeletons corresponding to d3 and d4 being
the MTD are also investigated and the corresponding (quantitatively similar)
results are given in the Appendix. Again, both the CRM with the standard
allocation criterion and the CRM with the novel criterion use the same model
parameters and the only difference is the selection rule. This allows to link the
observed differences to the criteria choice only. We study (i) the proportion of
the correct selections (PCS) and (ii) the proportion of patients experienced a
toxic response. We consider different values of a = {0.3, 0.4, 0.5} correspond-
ing to the approximate half-width of the intervals θ ≈ {0.00, 0.20, 0.25}.
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Fig 4. Six considered dose-toxicity scenarios for the comparison to the CRM. The MTD
is marked by the black triangle.
We denote the CRM with the new escalation criterion using parameter a
by CIBP(a). The characteristics of all the models compared are evaluated
in R (R Core Team, 2015) using the bcrm-package by Sweeting et al. (2013).
To accommodate the new criterion, the corresponding modifications to the
package were made.
4.2. Operating characteristics
Proportions of each dose selections and proportions of patients experienced a
DLT for CRM and for CIBP are given in Table 3. We use 40000 simulations
to declare any difference above 1% as a significant one.
Comparing the performance of CIBP for different values of the asymmetry
parameter, one can see that more conservative allocation and selection cor-
respond to CIBP(0.3). The greatest difference can be seen in scenarios 1 and
6. The increase in a from 0.3 to 0.5 leads to an increase in the PCS by 5% in
the toxic scenario 1 and to a decrease in the PCS by 3.5% in the flat scenario
6. The differences in the rest of scenarios are smaller, but still significant.
Overall, greater values of a favour higher doses to be selected and lead to a
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Table 3
Proportions of each dose selections and proportions of DLTs (Tox) in one trial for
CRM and CIBP using a = {0.3, 0.4, 0.5}. Results are based on 40000 simulations.
d1 d2 d3 d4 d5 d6 Tox
Scenario 1
Toxicity 25.00 35.00 37.50 40.00 45.00 50.00
CIBP(0.3) 69.18 21.65 6.18 2.27 0.61 0.11 28.31
CIBP(0.4) 66.40 22.20 7.25 3.08 0.91 0.16 29.46
CIBP(0.5) 64.12 22.25 8.49 3.80 1.15 0.18 30.58
CRM 65.59 21.16 8.22 3.79 1.07 0.17 30.17
Scenario 2
Toxicity 15.00 25.00 35.00 40.00 45.00 50.00
CIBP(0.3) 24.06 47.88 21.98 5.00 0.93 0.15 23.33
CIBP(0.4) 24.00 46.95 22.28 5.39 1.19 0.19 24.87
CIBP(0.5) 23.97 46.12 22.20 6.02 1.46 0.24 26.45
CRM 25.41 45.76 21.36 5.96 1.27 0.24 26.10
Scenario 3
Toxicity 10.00 15.00 25.00 35.00 45.00 50.00
CIBP(0.3) 4.26 25.61 46.48 20.20 3.16 0.28 20.91
CIBP(0.4) 4.08 25.53 46.25 20.57 3.23 0.34 22.56
CIBP(0.5) 3.77 25.64 46.49 20.46 3.31 0.32 24.21
CRM 3.91 26.66 45.62 20.37 3.06 0.37 23.97
Scenario 4
Toxicity 5.00 10.00 15.00 25.00 35.00 45.00
CIBP(0.3) 0.22 5.01 27.27 44.62 19.65 3.23 19.36
CIBP(0.4) 0.17 4.78 26.64 45.66 19.59 3.15 20.99
CIBP(0.5) 0.18 4.74 27.16 45.74 19.36 2.83 22.43
CRM 0.18 4.50 27.82 45.32 19.15 3.03 22.43
Scenario 5
Toxicity 2.50 5.00 10.00 15.00 25.00 35.00
CIBP(0.3) 0.00 0.34 6.54 27.67 43.34 22.11 17.71
CIBP(0.4) 0.00 0.31 5.89 27.77 44.12 21.89 19.24
CIBP(0.5) 0.00 0.33 5.50 28.06 44.84 21.28 20.73
CRM 0.01 0.27 5.46 28.89 44.10 21.28 20.56
Scenario 6
Toxicity 1.50 2.50 7.50 10.00 15.00 25.00
CIBP(0.3) 0.00 0.04 2.97 10.42 26.84 59.72 15.25
CIBP(0.4) 0.00 0.05 2.30 9.55 27.53 60.58 16.53
CIBP(0.5) 0.00 0.04 1.68 7.31 27.71 63.26 17.98
CRM 0.00 0.05 1.88 8.65 28.89 60.53 17.34
higher mean proportion of toxic responses with the difference around 2-3%
between CIBP(0.3) and CIBP(0.5) in all scenarios.
Regarding the comparison of CIBP and CRM, one can find that CIBP(0.4)
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has a similar PCS, but also a smaller proportion of toxic responses in all con-
sidered scenarios. The CIBP(0.5) performs similar (scenarios 2-5) or better
(scenario 6) than CRM at the cost of 1% decrease in the PCS in scenario
1. The most noticeable difference can be observed by comparing CRM to
CIBP(0.3). In terms of the PCS, CIBP(0.3) outperforms the CRM by 4%
and 2% in the most toxic scenarios 1, 2 and shows the comparable perfor-
mance in rest of scenarios. At the same time, CIBP(0.3) outperforms the
CRM in terms of the proportion of toxic responses in all considered scenario
by nearly 3% in scenarios 2-5 and by 2% in scenarios 1 and 6. While the mar-
gin of the difference might be seen to be negligibly small, this improvement
results in nearly 1 fewer patient experienced a DLT. Therefore, this design
is more ethical as it exposes fewer patients to more toxic doses while leading
to no changes or an increase in the PCS.
Another valuable feature of the novel allocation criterion is an additional
flexibility which allows controlling the number of toxic responses directly.
A clinician can choose the parameter a based on their conservatism and on
the range of scenarios of interest. For instance, a clinician might be ready to
sacrifice the PCS in the flat scenario 6 for the sake of not selecting overly
toxic dose in scenario 1. The new criterion enables such an option. At the
same time, the design preserves its simplicity and does not result in any extra
computational costs.
5. Comparison to the EWOC and its modifications
5.1. Setting
Alternative criteria for solving the ethical and uncertainty issues using the
two-parameter logistic model
ψ(di, β1, β2) =
exp(β1 + β2di)
1 + exp(β1 + β2di)
were proposed by Babb et al. (1998) using the EWOC design. However,
as stated above the EWOC can result in a systematic underestimation of
the MTD. Therefore, some modifications were proposed by Tighiouart et al.
(2010); Wheeler et al. (2017). The main idea beyond the modifications is to
use a changing parameter αn in the criterion (3) rather than a fixed value
α. The detailed description of these modifications can be found in Wheeler
et al. (2017). Alternatively, the BLRM method by Neuenschwander et al.
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(2008)also using the two-parameter logistic model and a loss function, can
be used. In this section, we compare the performance of the one-parameter
CRM design using the novel allocation rule to these designs.
We consider the setting by Wheeler et al. (2017) for discrete dose levels.
There are n = 40 patients and m = 6 doses in the trial. The goal is to find
the MTD corresponding to the γ = 0.33. The original scenarios are given in
Figure 5.
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Fig 5. Ten considered dose-toxicity scenarios for the comparison to EWOC. The MTD is
marked by the black triangle.
The prior distribution of β is specified as in the previous section. The only
difference is the skeleton which is now set using the same information as by
Wheeler et al. (2017): the prior MTD is d3. Assuming that ethical issues are
of the greater interest in this trial we consider a = {0.5, 0.25, 0.10}.
We compare the performance of the proposed approach to
• EWOC design - the original EWOC design using fixed α = 0.25
• TR design by (Tighiouart et al., 2010) using α2 = . . . = α9 = 0.25,
αn = min (αn−1 + 0.05, 0.50) for all future patients.
• Toxicity-dependent feasibility bound design (TDFB) by Wheeler et al.
(2017) using
αn+1 = min
(
0.50, αmin + (0.50− αminn− 1−
∑n
i=1 yi
S
)
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where n−1−∑ni=1 yi is number of patients with no DLTS, αmin = 0.25
and S = 122
3
. For both modifications of the EWOC design above we
use the parameters as in Wheeler et al. (2017).
• Design by Neuenschwander et al. (2008) (BLRM) which uses the loss
function for the decision. Following the original proposal we use the
same bivariate normal prior distribution for parameters as in the orig-
inal work and adapt the toxicity intervals for the loss function for
γ = 0.33
L =

1 if p ∈ (0.00, 0.26)
0 if p ∈ (0.26, 0.41)
1 if p ∈ (0.41, 0.66)
2 if p ∈ (0.66, 1.00)
Following Wheeler et al. (2017) we study the performance of designs in
terms of (i) Accuracy
A = 1−m
∑m
i=1 (pi − γ)2 pii∑m
i=1 (pi − γ)2
where pi is the true toxicity probability for di and pii is the probability to
select di and in terms of (ii) mean number of toxic responses (DLTs). As
many different scenarios are considered, one can expect that one design would
outperform another in some of them (Wages, 2015). Therefore, we focus on
average performance: the (geometric) mean accuracy and the mean number
of DLTs across all scenarios.
5.2. Operating characteristics
The accuracy index for the CIBP using a = {0.5, 0.25, 0.10}, TDFB, EWOC,
TR and BLRM design are given in Figure 6. Comparing CIBP for different
values of a, one can see that the mean accuracy decreases with parameter a.
Due to a more conservative allocation, fewer patients are assigned to doses
in the neighbourhood of the MTD. This results in a lower PCS and a lower
accuracy index. The decrease in the accuracy index is, however, rather small
- from 0.87 using a = 0.5 to 0.83 using a = 0.1. The most noticeable drop
across scenarios can be found in scenario 5 - 0.20. Clearly, the variance of the
accuracy indexes increases with decreasing a - a more conservative design
leads to a better performance in toxic scenarios 1-3 for the cost of a less
accurate performance in flat scenarios 8-10.
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Fig 6. Accuracy indices and mean accuracy indices for CIBP using a = {0.5, 0.25, 0.10},
TDFB, EWOC, TR and BLRM designs. The upper dashed horizontal line corresponds to
the accuracy of the TR and the lower one to the accuracy of the TDFB. Results are based
on 2000 simulations.
Comparing different approaches, TR, BLRM and CIBP(0.5) correspond to
the highest mean performance. However, TR corresponds to a slightly greater
variability of the accuracy indices between scenarios. The TDFB design per-
forms comparably to CIBP(0.25) design both in terms of the mean accuracy
and the accuracy variability. As expected, the original EWOC results in the
least mean accuracy index due to the large MTD underestimation in sce-
narios 5-7. The mean accuracy index associated with the most conservative
CIBP(0.10) is greater than associate with EWOC by 0.15. The accuracy in-
dices themselves are of a limited interest when considered alone with taking
into account the safety. The mean number of DLTs in all considered designs
are given in Figure 7.
Regarding CIBP, while lower values of a resulted in a lower accuracy they
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Fig 7. DLTs and mean number of DLTs for the CIBP using a = {0.5, 0.25, 0.10}, TDFB,
EWOC, TR and BLRM designs. The upper, middle and lower dashed horizontal lines
correspond to performance of TR, CIBP(0.25) and EWOC, respectively. Results are based
on 2000 simulations.
also result in fewer DLTs on average across all scenarios. As the result, the
mean number of DLTs is decreased by approximately 2 toxic responses com-
paring CIBP(0.5) and CIBP(0.10). Considering different designs, it is of in-
terest to compare designs which have comparable mean accuracy indices.
The TR and BLRM designs result in nearly 0.5 more toxic responses on
average than CIBP(0.5). The TDFB design that has the accuracy similar
to CIBP(0.4) results in nearly 1.5 excessive toxic responses than the novel
design. Interestingly, the EWOC, which had the mean accuracy index lower
than CIBP(0.1) by 0.15, results in a similar mean number of DLTs across
all scenarios as well as CIBP(0.10). Interestingly, it also leads to nearly one
additional patient with a toxic response in highly toxic scenarios 1 and 2.
Overall, in contrast to TDFB and TR, the proposed design does not change
the parameter of conservatism as more patients are trialled. It requires only
one extra parameter to be specified. However, one can find a value of param-
eter a that would lead to similar accuracy index, but a fewer mean number
of DLTs in all scenarios. At the same time, the safest version of the CIBP
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design results in comparable to the EWOC mean number of DLTs across all
scenarios, but also in a noticeably greater accuracy.
6. Discussion
The novel dose-escalation criterion for the allocation of patients is introduced
in this work. The criterion requires only one additional parameter, which has
clear intuitive interpretation and can be easily tuned according to the pur-
poses of the investigator, to be specified. A guideline on the choice of param-
eter is also given. We incorporate this criterion into the one-parameter power
Bayesian CRM method which has shown to be a powerful tool to identify the
MTD. It is found that the proposed design results in fewer number of toxic
responses in a trial than the original CRM with no loss in the probability of
correct selections. Comparing the novel design to alternative approaches, we
have found that there exists a value of the asymmetry parameter such that
the design would have a similar accuracy, but a lower mean number of toxic
responses. Therefore, the new criterion allows to make model-based designs
more ethical as it decreases the number of patients experienced DLTs but
does not lead to any decrease in accuracy.
Importantly, the novel criterion proposed in this work can be applied to
any parametric model and not limited to the one-parameter model. The
application of the criterion was demonstrated in the context of a single-
agent trial only. As there are generalisations of the CRM design for more
complex studies, it is also of interest to consider the application of the novel
allocation rule to dose-combination and dose-schedule trials including the
case of delayed toxicity responses.
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Table 4
Proportions of doses selections and the proportion of DLTs (TR) in one trial for
the CRM and the CIBP using a = {0.3, 0.4, 0.5} and the prior parameter as
described in Section 4, but the prior MTD d3 is used for the skeleton
construction. Results are based on 40000 simulations.
d1 d2 d3 d4 d5 d6 TR
Scenario 1
Toxicity 25.00 35.00 37.50 40.00 45.00 50.00
CIBP (0.3) 67.59 22.50 6.44 2.60 0.74 0.13 28.73
CIBP (0.4) 64.12 22.53 8.29 3.77 1.08 0.21 29.98
CIBP (0.5) 61.78 22.23 9.61 4.80 1.30 0.28 31.31
CRM 63.27 21.28 9.45 4.52 1.28 0.21 31.02
Scenario 2
Toxicity 15.00 25.00 35.00 40.00 45.00 50.00
CIBP (0.3) 22.86 47.00 23.37 5.45 1.15 0.17 23.94
CIBP (0.4) 22.89 45.59 23.64 6.25 1.40 0.23 25.64
CIBP (0.5) 23.47 44.65 23.12 6.97 1.49 0.29 27.14
CRM 24.38 44.26 22.64 6.81 1.64 0.27 27.23
Scenario 3
Toxicity 10.00 15.00 25.00 35.00 45.00 50.00
CIBP (0.3) 3.76 23.83 46.95 21.62 3.51 0.33 21.74
CIBP (0.4) 3.84 23.95 46.45 21.98 3.47 0.32 23.25
CIBP (0.5) 3.53 23.99 46.36 22.17 3.56 0.40 25.09
CRM 3.52 24.57 46.51 21.54 3.50 0.37 25.17
Scenario 4
Toxicity 5.00 10.00 15.00 25.00 35.00 45.00
CIBP (0.3) 0.17 4.45 25.60 46.06 20.42 3.29 20.10
CIBP (0.4) 0.16 4.15 25.51 46.38 20.60 3.20 21.62
CIBP (0.5) 0.15 4.00 25.66 46.66 20.38 3.14 23.37
CRM 0.18 4.08 26.25 46.39 20.24 2.85 23.40
Scenario 5
Toxicity 2.50 5.00 10.00 15.00 25.00 35.00
CIBP (0.3) 0.00 0.27 5.71 27.24 44.13 22.64 18.39
CIBP (0.4) 0.00 0.24 5.06 26.41 45.88 22.41 19.96
CIBP (0.5) 0.00 0.27 4.97 27.23 45.48 22.05 21.41
CRM 0.00 0.25 4.58 27.98 45.88 21.31 21.56
Scenario 6
Toxicity 1.50 2.50 10.00 10.00 15.00 25.00
CIBP (0.3) 0.00 0.02 2.42 9.37 26.83 61.36 15.83
CIBP (0.4) 0.00 0.02 1.74 7.62 27.18 63.44 17.20
CIBP (0.5) 0.00 0.05 1.74 7.75 27.89 62.58 18.20
CRM 0.00 0.04 1.29 6.63 28.55 63.49 18.36
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Table 5
Proportions of doses selections and the proportion of DLTs (TR) in one trial for
the CRM and the CIBP using a = {0.3, 0.4, 0.5} and the prior parameter as
described in Section 4, but the prior MTD d4 is used for the skeleton
construction. Results are based on 40000 simulations.
d1 d2 d3 d4 d5 d6 TR
Scenario 1
Toxicity 25.00 35.00 37.50 40.00 45.00 50.00
CIBP (0.3) 64.38 23.48 7.74 3.21 1.03 0.15 29.25
CIBP (0.4) 62.80 22.43 9.04 4.15 1.35 0.24 30.56
CIBP (0.5) 59.16 22.61 10.51 5.68 1.73 0.31 31.93
CRM 60.09 21.50 10.73 5.63 1.74 0.30 31.96
Scenario 2
Toxicity 15.00 25.00 35.00 40.00 45.00 50.00
CIBP (0.3) 21.23 46.23 24.93 6.07 1.36 0.18 24.61
CIBP (0.4) 21.78 44.21 25.04 6.94 1.74 0.29 26.46
CIBP (0.5) 22.46 43.10 24.44 7.82 1.87 0.31 27.91
CRM 23.79 42.60 23.60 7.78 1.92 0.32 28.17
Scenario 3
Toxicity 10.00 15.00 25.00 35.00 45.00 50.00
CIBP (0.3) 3.50 22.07 47.11 23.09 3.92 0.31 22.38
CIBP (0.4) 3.37 21.87 46.68 23.73 3.97 0.38 24.31
CIBP (0.5) 3.54 22.51 46.14 23.47 3.93 0.41 25.67
CRM 3.53 23.31 45.96 22.88 3.89 0.44 26.19
Scenario 4
Toxicity 5.00 10.00 15.00 25.00 35.00 45.00
CIBP (0.3) 0.13 3.62 23.72 47.04 22.04 3.44 20.85
CIBP (0.4) 0.16 3.71 23.79 47.30 21.75 3.29 22.57
CIBP (0.5) 0.15 3.67 24.02 47.06 21.78 3.31 23.99
CRM 0.15 3.56 24.48 47.12 21.39 3.30 24.57
Scenario 5
Toxicity 2.50 5.00 10.00 15.00 25.00 35.00
CIBP (0.3) 0.00 0.20 4.69 25.61 45.86 23.64 19.11
CIBP (0.4) 0.00 0.22 4.35 25.54 46.44 23.44 20.82
CIBP (0.5) 0.00 0.21 4.14 25.68 46.36 23.61 22.10
CRM 0.00 0.23 4.09 26.50 46.24 22.94 22.45
Scenario 6
Toxicity 1.50 2.50 10.00 10.00 15.00 25.00
CIBP (0.3) 0.00 0.03 1.74 8.63 26.63 62.97 16.33
CIBP (0.4) 0.00 0.03 1.33 6.53 25.96 66.16 18.01
CIBP (0.5) 0.00 0.02 1.24 6.20 26.59 65.94 18.88
CRM 0.00 0.05 1.17 6.44 27.95 64.38 18.88
